Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results)

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/29942

Title:	Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results)
Authors:	Vermersch, P. Eralinna, J. -P. Nicholas, R. Oreja-Guevara, C. Siva, A. VAN WIJMEERSCH, Bart Wiendl, H. Buffels, R. Kuhelj, R. Wei, W. Comi, G.
Issue Date:	2019
Publisher:	SAGE PUBLICATIONS LTD
Source:	MULTIPLE SCLEROSIS JOURNAL, 25(SI), p. 344-345 (Art N° P690)
Notes:	[Vermersch, P.] Univ Lille, Lille, France. [Eralinna, J. -P.] NEO Res, Turku, Finland. [Nicholas, R.] Imperial Coll Healthcare NHS Trust, London, England. [Nicholas, R.] Imperial Coll, London, England. [Oreja-Guevara, C.] Hosp Clin San Carlos, Madrid, Spain. [Siva, A.] Istanbul Univ, Cerrahpasa Sch Med, Cerrahpasa, Turkey. [Van Wijmeersch, B.] Univ Hasselt, Overpelt, Belgium. [Van Wijmeersch, B.] Rehabil & MS Ctr Overpelt, Overpelt, Belgium. [Wiendl, H.] Univ Munster, Munster, Germany. [Buffels, R.; Kuhelj, R.; Wei, W.] F Hoffmann La Roche Ltd, Basel, Switzerland. [Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy.
Keywords:	Clinical Neurology; Neurosciences
Document URI:	http://hdl.handle.net/1942/29942
ISSN:	1352-4585
e-ISSN:	1477-0970
ISI #:	000485303101246
Category:	M
Type:	Journal Contribution
Appears in Collections:	Research publications

1

checked on Apr 16, 2024

76

checked on Jul 31, 2023

Check